

OPEN ACCESS

EDITED AND REVIEWED BY
Michel Goldman,
Université Libre de Bruxelles, Belgium

*CORRESPONDENCE
Alice P. Chen

Chen.PrecisionMedicine@gmail.com

RECEIVED 07 May 2023 ACCEPTED 26 June 2023 PUBLISHED 11 July 2023

CITATION

Chen AP and Tan A (2023) Editorial: Women in science—Precision medicine 2021. Front. Med. 10:1218579. doi: 10.3389/fmed.2023.1218579

COPYRIGHT

© 2023 Chen and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are

forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Women in science—Precision medicine 2021

Alice P. Chen1* and Antoinette Tan2

¹AP Consultant, Potomac, MD, United States, ²Levine Cancer Institute, Atrium Health, Charlotte, NC, United States

KEYWORDS

women scientist, CYP polymorphism, craniopharyangioma, obesity, hypertension

Editorial on the Research Topic

Women in science—Precision medicine 2021

Recently, while attending the Precision Medicine and Functional Genomics 2022 Symposium, I heard Her Excellency Dr. Maryam Matar present on Precision Health in the United Arab Emerits. Her remarkable work served as a powerful reminder of the vital role women play in the field of science. As a matter of fact, 35% of the presenters at the meeting were female. While the halls of science were once dominated by men, these days the unmistakable sound of high heel pumps can be heard echoing through them. This Research Topic, *Women in science-Precision medicine 2021*, to celebrate the invaluable contributions of female scientists as they advance the frontiers of science.

In the eight manuscripts presented here, we have leading female authors hailing from over four countries and three continents, representing a diverse range of institutions, and tackling topics spanning from bench to bedside. Among the papers, three focus on topics related to careful observations of new case reports of unusual tumors, obesity in relation to dosing for cancer treatment, and the influence of CYP2D6 and CYP3A5 polymorphisms specifically in bisoprolol treatment of Chinese hypertensive patients. Identifying pharmacokinetics and pharmacodynamics with biomarkers in ethnicity, particularly outside the Caucasian population, is of utmost importance. These brilliant female investigators possess an incredible ability to recognize even the smallest changes and uncover crucial medical findings from these subtle differences that may be overlooked by others.

Additionally, seven of the articles in this Research Topic are in the field of oncology, addressing various aspects of precision medicine in this rapidly developing area. These women explore topics ranging from the fundamentals of how to properly dose patients to the intricate mechanisms of developing agents in the age of molecular targets. Their research covers a wide spectrum of cancers, from the most common, such as breast cancer, to the rare craniopharyangioma. These scientists are also delving into preclinical studies to understand the origins of cancer, pathways, and clinical studies to examine patient response to treatment.

We are thrilled to present this topic and highlight the success of the vast array of women scientists making their mark in every corner of science. I eagerly anticipate the next round of female scientists who will share their findings under the new Research Topic: Women in Science–Precision Medicine 2023.

Chen and Tan 10.3389/fmed.2023.1218579

Author contributions

AC worked on the Research Topic, edited some of the manuscripts, and wrote the editorial. AT worked on the Research Topic, edited some of the manuscript, and reviewed and revised the editorial. All authors contributed to the article and approved the submitted version.

Conflict of interest

AC was employed by AP Consultant.

The remaining author declares that the research was conducted in the absence of any commercial or financial

relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.